Surface Logix Reports Data on SLx-2101 for Erectile Dysfunction at The American Urological Association Meeting

Search Blogs that Mention this News Release

Click this link to view linked Bookmarking Services

Click this link to view linked Blogging Services

Surface Logix Reports Data on SLx-2101 for Erectile Dysfunction at The American Urological Association Meeting

    BOSTON, May 23 /PRNewswire/ -- Surface Logix announced that Dr. Irwin
Goldstein, a leading expert on sexual health and Editor-in-Chief, The
Journal of Sexual Medicine, presented results from the first clinical study
of SLx-2101 at the 2006 American Urological Association (AUA) meeting in
Atlanta, GA. SLx-2101 is a novel, long acting PDE-5 inhibitor for the
management of disorders associated with endothelial dysfunction, including
erectile dysfunction.
    The Phase I study demonstrated that SLx-2101 has a favorable safety,
tolerability, pharmacokinetic and pharmacodynamic profile in healthy male
volunteers. SLx-2101 is now completing a Phase IIa trial in patients with
erectile dysfunction.
    "I continue to be impressed with the data on SLx-2101 and was pleased
to present the results at the AUA," notes Dr. Goldstein. "The preliminary
Rigiscan data from the Phase IIa study shows that this drug is working at
48 hours after a single dose of 10mg and this is the first objective study
of this type where I have seen confirmed efficacy for a PDE-5 inhibitor
well beyond 36 hours."
    Dr. Goldstein adds, "The developing profile of SLx-2101 with rapid
onset and long duration suggests that it could well become the new gold
standard for treating erectile dysfunction and other PDE-5 related
disorders."
    "We are extremely pleased with the progress of SLx-2101 in the clinic,"
comments Dr. William Prince, Chief Development Officer of Surface Logix,
"The preliminary data from our Phase IIa study has surpassed our
expectations and allows us to include other indications, outside of
erectile dysfunction, in our development plans for SLx-2101. We plan to
initiate additional Phase II studies by the end of this year and we look
forward to reporting the results of these studies at the appropriate
scientific forums next year."
    About the Phase I Study
    In a double-blind, placebo controlled, randomized study, healthy male
volunteers received single oral doses of SLx-2101 or placebo. Five dose
levels were included and subjects were monitored for adverse events and
pharmacokinetic sampling was performed out to 48 hours post dose. Two
methods of assessing pharmacodynamic activity were included in the study.
Erectile response was assessed over 24 hours using the Rigiscan(TM) Plus
system and peripheral arterial tone was assessed using the Endo-PAT2000(TM)
device.
    About SLx-2101, Erectile and Endothelial Dysfunction
    SLx-2101 is an oral phosphodiesterase-5 (PDE-5) inhibitor designed
using Surface Logix' proprietary small molecule Pharmacomer(TM) Technology.
SLx-2101 is being developed to treat endothelial dysfunction, a
physiological disability of endothelial cells, the cells that line the
inner surface of all blood vessels, arteries and veins, that prevents them
from carrying out their normal biochemical functions. Normal endothelial
cells are involved in mediating the processes of coagulation, platelet
adhesion, immune function, control of volume and electrolyte content of the
intravascular and extravascular spaces. Endothelial dysfunction is believed
to be a major contributor to the development of several major diseases
including atherosclerosis, pulmonary hypertension, hypertension and
erectile dysfunction.
    About Surface Logix Inc.
    Surface Logix Inc. uses its expertise in biophysical chemistry to
create new small molecule drugs that are optimized to meet the challenges
of human physiology. The company is advancing multiple internal programs
focused primarily on cardiovascular disease, oncology and metabolic
disorders and works with strategic partners to create differentiated new
chemical entities. For more information, please visit
http://www.surfacelogix.com.
    Contact:
    David H. Donabedian, Ph.D.
    Vice President, Business Development
    617.746.8520

    Media:
    Kari Watson
    MacDougall Biomedical Communications Inc.
    kwatson@macbiocom.com
    508.647.0209

SOURCE Surface Logix Inc.

http://www.surfacelogix.com
CONTACT:
David H. Donabedian, Ph.D., Vice President,
Business Development of Surface Logix, +1-617-746-8520; or Kari
Watson of MacDougall Biomedical Communications Inc.,
+1-508-647-0209, kwatson@macbiocom.com